Anixa Biosciences Inc. (ANIX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Anixa Biosciences Inc. (NASDAQ: ANIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.99 (-4.17% 1D, market cap $103.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ANIX ranks #538 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLLS (Cellectis S.A.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $104.0M) and PMVP (PMV Pharmaceuticals Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $103.5M). Among the 5-stock peer group, ANIX leads on earnings multiple (N/A) while ANIX leads on capital efficiency (-35.0% ROIC).
Per ANIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0000715446), Anixa Biosciences Inc. generated $32.8M in revenue (+15501.3% YoY), -$10.9M in net income, and -$7.2M in free cash flow against $15.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.4% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ANIX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.95) and Max Pain ($3.14) forces dealer call-delta covering toward $5.73.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Anixa Biosciences Inc. (ANIX) dropped -4.17% to $2.99, trading at 21% of its 52-week range ($2.32 – $5.46). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
- SEC Filing
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth cohort in its ongoin
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15501.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ANIX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ANIX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Anixa Biosciences Inc. (ANIX) ranks #538 by composite RQD confidence (37/100, grade D-) and #645 by equity capitalization ($103.9M). Within this direct 5-issuer industry benchmark cohort, ANIX leads on earnings valuation at N/A trailing P/E, while ANIX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CLLS currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with ANIX at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANIX
ACTIVE
Anixa Biosciences Inc. | D- | 37/100 | — | — | -35.0% | -4.17% | $103.9M | Benchmark Subject |
| CLLS Cellectis S.A. | D | 45/100 | — | — | — | -4.17% | $104.0M | /clls-vs-anix → |
| PMVP PMV Pharmaceuticals Inc. | D- | 42/100 | — | — | -35.0% | +4.58% | $103.5M | /pmvp-vs-anix → |
| OKUR OnKure Therapeutics Inc. (Class A) | E | 34/100 | — | — | -35.0% | -1.14% | $104.9M | /okur-vs-anix → |
| IMUX Immunic Inc. | E | 33/100 | — | — | -35.0% | -2.26% | $100.2M | /imux-vs-anix → |
In its most recent audited fiscal period (FY2025, filed 2025-10-31), Anixa Biosciences Inc. (ANIX) reported GAAP revenue of $32.8M (+15501.3% vs. FY2024 revenue of $210.0K , and +15501.3% cumulative change since FY2023) , GAAP net income of -$10.9M, operating cash flow of -$7.2M, and free cash flow of -$7.2M (+2.2% YoY). On the balance sheet, ANIX closed FY2025 with $15.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-10-31 | $32.8M | -$10.9M | -$7.2M | -$7.2M | $15.2M | — |
| FY2024 (FY) | 2024-10-31 | $210.0K | -$12.6M | -$7.3M | -$7.3M | $18.9M | — |
| FY2023 (FY) | 2023-10-31 | $210.0K | -$9.8M | -$6.2M | -$6.2M | — | — |
As of 2026-11-03, Anixa Biosciences Inc. (NASDAQ: ANIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.99 (-4.17% 1D, market cap $103.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ANIX ranks #538 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLLS (Cellectis S.A.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $104.0M) and PMVP (PMV Pharmaceuticals Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $103.5M). Among the 5-stock peer group, ANIX leads on earnings multiple (N/A) while ANIX leads on capital efficiency (-35.0% ROIC).
Per ANIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0000715446), Anixa Biosciences Inc. generated $32.8M in revenue (+15501.3% YoY), -$10.9M in net income, and -$7.2M in free cash flow against $15.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ANIX last traded at $2.99 (-4.17% on volume of 128,352 shares), positioning the stock +1.36% above its 50-day simple moving average ($2.95) and +0.67% above its 200-day simple moving average ($2.97). Across its 52-week range of $2.32 to $5.46, ANIX sits at the 21.3% percentile with a 14-day RSI of 50.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.4% ($2.62 to $3.36).
Anixa Biosciences Inc. (ANIX) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.99 (-4.17% 1D, market capitalization $103.9M).
Anixa Biosciences Inc. (ANIX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is a publicly traded biotechnology company with a market capitalization of $0.1B. Per the recent news wire, the company's stated focus includes CAR-T therapy for ovarian cancer and a breast cancer vaccine.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-10-31), Anixa Biosciences Inc. (ANIX) reported $32.8M in annual revenue (up from $210.0K in FY2024, +15501.3% YoY) and -$10.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($210.0K revenue, -$9.8M net income) through FY2025, ANIX scaled operating cash flow to -$7.2M and free cash flow to -$7.2M, backed by $15.2M in total assets against $0 in total debt.
Supply chain: NONE. Butterfly links: none. Proprietary signals: none. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be mapped from the source data. A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from partners, suppliers, or customers. Watch items drawn from the other sections: dependence on external funding given negative free cash flow, and the sensitivity of clinical-stage sentiment to news flow described above.
Real-time company headlines, analyst actions, and sector developments for Anixa Biosciences Inc. (ANIX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on ANIX here at $3.12: Insider purchases by a director and insider Amit Kumar, alongside reported survival data in ovarian cancer patients, point to possible conviction in the company's pipeline.. Compare ANIX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.96 are getting bought.
@BearTrap_Alert Shorting a 10/20 institutional whale-flow stock at $3.12 is dangerous when funds are rotating into Health Care.
I respect the product at Anixa Biosciences Inc., but the stock at $3.12 is a different story. Negative operating income of -$11.7M and free cash flow of -$7.2M against only $1.5M in cash, with ROIC at -35%, leave the company dependent on external funding.. FCF yield is -6.25% and RQD sits at 37/100 (D-) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: